Etrasimod | search
Click here to view Etrasimod news from 60+ newspapers.
Bookmark or Share- Etrasimod - WikipediaEtrasimod, sold under the brand name Velsipity, is a medication that is used for the treatment of ulcerative colitis. It is a selective sphingosine-1-phosphate (S1P) receptor modulator that modifies the activity of the immune system. It is taken by mouth. The most common side effects include lymphopenia (low levels of lymphocytes) and headache.
- U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to ...NEW YORK-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC).
- Pfizer Announces Positive Top-Line Results for Phase 3 Trial of ...About Etrasimod. Etrasimod is an oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator being investigated for a range of immuno-inflammatory diseases including ulcerative colitis, Crohn’s Disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata.
- Etrasimod as induction and maintenance therapy for ulcerative colitis ...Etrasimod, a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively activates S1P receptor subtypes 1, 4, and 5, with no detectable activity on S1P 2,3, is in development for the treatment of immune-mediated diseases, including ulcerative colitis.
- Official Patient Website | VELSIPITY® (Etrasimod)Official Patient Website | VELSIPITY® (Etrasimod) For adults with moderate to severe ulcerative colitis (UC) Some saw remission by week 12, with fewer bathroom trips and less rectal bleeding. One pill, once a day. Discover VELSIPITY, the newest FDA-approved medicine of its class for adults with moderate to severe UC.
More
